TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8357888
Drug: Nonprescription medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprescription medication use
Study: 8357888
Drug: Knowledge and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge and compliance with medication
Study: 8357888
Drug: Multiple medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple medication use and wellbeing
Study: 31801597
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy maintained before surgery
Study: 31801597
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy interrupted and substituted with subcutaneous heparin
Study: 28932091
Drug: Fixed-time split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-time split dose regimen
Study: 28932091
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose regimen
Study: 21272401
Drug: Ground hazelnuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground hazelnuts (30 g/d)
Study: 21272401
Drug: Sliced hazelnuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliced hazelnuts (30 g/d)
Study: 21272401
Drug: Whole hazelnuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole hazelnuts (30 g/d)
Study: 15636254
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of iodine (3-4 times a day as eye drops)
Study: 9142433
Drug: Pimobendan 2.5
Normalized name: pimobendan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 2.5 mg single oral dose
Study: 9142433
Drug: Pimobendan 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 5.0 mg single oral dose
Study: 9142433
Drug: Pimobendan 2.5
Normalized name: pimobendan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 2.5 mg b.i.d. for 8 weeks
Study: 9142433
Drug: Pimobendan 1.25
Normalized name: pimobendan 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 1.25 mg and 2.5 mg b.i.d. long-term treatment
Study: 27806235
Drug: BIA 10‐2474
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 10‐2474 (50 mg per day)
Study: 24496169
Drug: Combined lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 μg/mL
Study: 17417075
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halofantrine (HF) 500 mg alone
Study: 17417075
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halofantrine (HF) 500 mg with prior administration of amodiaquine (AQ) 600 mg
Study: 16311142
Drug: Olanzapine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (20 mg/day)
Study: 12730556
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg/d
Study: 2025853
Drug: 4250 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4250 cGy in 25 daily fractions for 5 weeks (Group 1)
Study: 2025853
Drug: 4500 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4500 cGy in 25 daily fractions for 5 weeks (Group 2)
Study: 2025853
Drug: 5100 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5100 cGy in 30 daily fractions for 6 weeks (Group 3)
Study: 2025853
Drug: Tumor grade,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor grade, pathologic stage, whole‐pelvis radiation dose, and the use of brachytherapy
Study: 30958353
Drug: D-Cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-Cycloserine (DCS) 15 mg BID
Study: 26683109
Drug: TRV130 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 2 mg q3h
Study: 26683109
Drug: TRV130 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 3 mg q3h
Study: 26683109
Drug: Morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 4 mg q4h
Study: 26683109
Drug: TRV130 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 2 mg
Study: 26683109
Drug: TRV130 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 3 mg
Study: 22395582
Drug: CT gel
Normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Study: 22395582
Drug: CT gel
Normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT gel
Study: 9585312
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 45 s (Group 1)
Study: 9585312
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 60 s (Group 2)
Study: 9585312
Drug: Vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.01 mg/kg followed by thiopental and succinylcholine 1.5 mg/kg; intubation after 60 s (Group 3)
Study: 72192
Drug: Oral non-absorbed
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral non-absorbed antibiotics
Study: 23866300
Drug: Ziprasidone 20‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 20‐160 mg/day
Study: 23866300
Drug: Olanzapine 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5‐20 mg/day
Study: 15116057
Drug: Docetaxel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (10 mg/m²) with ketoconazole (200 mg once daily for 3 days)
Study: 9453428
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1 g per day orally)
Study: 2183879
Drug: Diazepam 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.20 mg/kg
Study: 30629285
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide 10 mg
Study: 18950300
Drug: Insulin-treated diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-treated diabetic patients
Study: 9207639
Drug: Non-insulin-treated diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-treated diabetic patients
Study: 15136070
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg daily
Study: 11230834
Drug: Eptifibatide with
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide with heparin
Study: 11230834
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with heparin
Study: 11230834
Drug: Eptifibatide without
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide without heparin
Study: 11230834
Drug: Placebo without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without heparin
Study: 8963818
Drug: 5.00- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.00- to 6.00-mm multizone treatment
Study: 6608581
Drug: Moxalactam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (200 mg/kg/day)
Study: 6608581
Drug: Ampicillin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (400 mg/kg/day) plus chloramphenicol (75 mg/kg/day)
Study: 26307133
Drug: CPS therapy
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPS therapy (Carboplatin, Paclitaxel, and Sorafenib)
Study: 26307133
Drug: CP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP therapy (Carboplatin and Paclitaxel)
Study: 22178164
Drug: Transvaginal ultrasound-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal ultrasound-guided embryo aspiration plus local administration of low-dose methotrexate (MTX)
Study: 22178164
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of MTX plus curettage with hysteroscopy (control group)
Study: 21146010
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antibiotics during CVAP placement
Study: 21146010
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics during CVAP placement
Study: 17096683
Drug: Quinidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (4 mg kg(‐1) infusion for 20 min)
Study: 10533479
Drug: Third intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third intensification block of chemotherapy (including dexamethasone)
Study: 10533479
Drug: Continuing chemotherapy
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing chemotherapy
Study: 7762325
Drug: Repeat FNA
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat FNA (with or without suppressive therapy)
Study: 28795387
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/day orally)
Study: 31553438
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 i.v.)
Study: 22128294
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 µg vaginally) after 200 mg mifepristone
Study: 17576325
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg ketoconazole
Study: 17576325
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 300 mg fluconazole with 2 weeks interval
Study: 15168391
Drug: MMF (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (1,000 mg) + Ferrous sulfate (105 mg) coadministered
Study: 15168391
Drug: MMF (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (1,000 mg) + Ferrous sulfate (4 hours later)
Study: 15168391
Drug: MMF (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (1,000 mg) alone (control)
Study: 11452246
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg, 1.2 mg, and 3.6 mg administered intraligamentarily
Study: 11452246
Drug: Morphine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1.2 mg administered subcutaneously
Study: 11452246
Drug: Morphine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1.2 mg and Fentanyl 50 microg administered submucosally
Study: 9570649
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii 113 g twice daily
Study: 7799581
Drug: Combined endolymphatic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endolymphatic therapy (lymph irradiation with helium-neon laser and direct endolymphatic antibacterial therapy)
Study: 3287907
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg
Study: 31455324
Drug: Mobile outreach
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile outreach team treatment (DOTS regime)
Study: 31455324
Drug: Facility-based DOTS
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facility-based DOTS treatment
Study: 31455324
Drug: Mobile outreach
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile outreach team treatment
Study: 22747323
Drug: RRGICB (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRGICB (combination of RRGI and CB)
Study: 21309489
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target effect-site concentration (Ce) of 0.5 ng/ml
Study: 21309489
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target effect-site concentration (Ce) of 1 ng/ml
Study: 21309489
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target effect-site concentration (Ce) of 2 ng/ml
Study: 21309489
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at target effect-site concentration (Ce) of 4 ng/ml
Study: 10542978
Drug: Calibration with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibration with a 3000 ml syringe
Study: 106982
Drug: 5 antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 antiinflammatory drugs
Study: 30428049
Drug: Pimodivir 300
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 300 mg
Study: 30098042
Drug: Pimodivir 600
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 600 mg
Study: 30428049
Drug: Pimodivir 600
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 600 mg plus Oseltamivir 75 mg
Study: 26739013
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive medication
Study: 18575277
Drug: 100-g OGTT
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g OGTT
Study: 15909229
Drug: Omnilux Revive
Normalized name: carboxymethylcellulose sodium Ophthalmic Solution [Revive Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnilux Revive facial treatment (20 min treatments, three times a week for three weeks)
Study: 15909229
Drug: Omnilux Revive
Normalized name: carboxymethylcellulose sodium Ophthalmic Solution [Revive Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnilux Revive facial treatment
Study: 12217597
Drug: Infliximab 5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 5mg/kg IV + Prednisone 40 mg/day for 28 days
Study: 12217597
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Prednisone 40 mg/day for 28 days
Study: 7779142
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg t.i.d.) and Indometacin (25 mg b.i.d.)
Study: 6253067
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks)
Study: 6253067
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks) and CCNU (70 mg/m2 every 6 weeks)
Study: 6253067
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m2 every 3 weeks), CCNU (70 mg/m2 every 6 weeks), and doxorubicin (40 mg/m2 every 3 weeks)
Study: 19351731
Drug: l-arginine/GHRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/GHRH infusion
Study: 19351731
Drug: l-arginine/GHRP-2 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine/GHRP-2 infusion
Study: 18843793
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein restriction (0.95 g kg(‐1) of body weight per day) for 3 weeks
Study: 12409984
Drug: Fasudil 5
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 5 mg TID
Study: 12409984
Drug: Fasudil 10
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 10 mg TID
Study: 12409984
Drug: Fasudil 20
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 20 mg TID
Study: 12409984
Drug: Fasudil 40
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 40 mg TID
Study: 12409984
Drug: Fasudil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (various doses)
Study: 409315
Drug: Cromolyn sodium,
Normalized name: Cromolyn Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn sodium, administered for four weeks
Study: 31399275
Drug: Adjuvanted 0.5
Normalized name: anthrax vaccine adsorbed, adjuvanted 0.5 mL/dose INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 0.5 μg total viral protein (TP) with Al(OH)3
Study: 31399275
Drug: Adjuvanted 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted 1.0 μg total viral protein (TP) with Al(OH)3
Study: 31399275
Drug: Non-adjuvanted 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted 1.0 μg total viral protein (TP)
Study: 29229209
Drug: AV-101 (l-4-chlorokynurenine)
Normalized name: 4-hydroxy-L-phenylalanine
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (l-4-chlorokynurenine) at doses of 30-1800mg (Phase 1A) and 360, 1080, 1440mg/day (Phase 1B) administered orally for 14 days.
Study: 29229209
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally for 14 days.
Study: 23241479
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and implant naltrexone
Study: 19593797
Drug: R-CHOP +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP + bortezomib (Arm A: 1 mg/m²; Arm B: 1.3 mg/m²)
Study: 19593797
Drug: R-CHOP +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP + bortezomib (Arm A: 1.3 mg/m²; Arm B: 1.6 mg/m²)
Study: 15119909
Drug: Extended-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbamazepine (ERC-CBZ) at a mean dose of 756.44 mg/day
Study: 8112490
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (general)
Study: 2467135
Drug: Amlodipine 2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5-5.0 mg (medium-dose group)
Study: 2467135
Drug: Amlodipine 5.0-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5.0-10.0 mg (high-dose group)
Study: 2467135
Drug: Amlodipine 1.25-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 1.25-2.5 mg (low-dose group)
Study: 17072702
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg oral clonidine and 20 mg raftidine (clonidine group; n = 41)
Study: 17072702
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg raftidine only (control group; n = 41)
Study: 14574247
Drug: Implant technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant technique of scleral buckling
Study: 14574247
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant and explant techniques
Study: 10997364
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 100,000 IU vitamin A
Study: 8959519
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.i.d.) plus Amoxycillin (750 mg t.i.d.) for 2 weeks
Study: 8959519
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg b.i.d.) plus Clarithromycin (500 mg t.i.d.) for 2 weeks
Study: 8959519
Drug: Second consecutive
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second consecutive dual therapy (either omeprazole plus amoxycillin or omeprazole plus clarithromycin)
Study: 1526681
Drug: Cefodizime (CDZ)
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (CDZ) 1 g i.m. b.i.d. for eight days
Study: 4089792
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Hep)
Study: 4089792
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + dihydroergotamine (DHE-Hep)
Study: 4089792
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + sulphinpyrazone (Sulph-Hep)
Study: 24113340
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-frequency repetitive transcranial magnetic stimulation and traditional eye-hand integration training
Study: 18195202
Drug: Ergocalciferol, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol, 1000 IU/d, plus calcium citrate, 1000 mg/d
Study: 18195202
Drug: Calcium citrate,
Normalized name: calcium citrate, calcium malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium citrate, 1000 mg/d (control group)
Study: 15903123
Drug: Alfuzosin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (40 mg)
Study: 12553387
Drug: Thiopental (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Study: 12553387
Drug: Thiopental (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (7 mg kg(‐1)), succinylcholine (1.5 mg kg(‐1))
Study: 12553387
Drug: Thiopental (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (7 mg kg(‐1)), fentanyl (2 microg kg(‐1)), cisatracurium (0.1 mg kg(‐1))
Study: 6222756
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oxytetracycline tablets taken twice daily
Study: 23615791
Drug: TB‐402 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB‐402 25 mg
Study: 23615791
Drug: TB‐402 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB‐402 50 mg
Study: 22058101
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dalfampridine under fasted condition (no food for 10-12 hours)
Study: 22058101
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dalfampridine under fed condition (after a high-fat meal)
Study: 15222825
Drug: Implementation intentions
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation intentions for home blood glucose monitoring, 4 times daily for 3 weeks
Study: 8547077
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rhIL-3
Study: 1670783
Drug: Antihistamine-decongestant
Normalized name: Antihistamine-Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-decongestant